Diabetes, Kidney Disease and Preserved Ejection Fraction

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Diabetes

Kidney Disease

Preserved Ejection Fraction

Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR?Preserved analysis

European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Prior studies were able to show that sodium–glucose cotransporter 2 inhibitors may reduce the incidence of LRTI in patients with type 2 diabetes. Patients who developed LRTI had a 2.7-fold

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

JULY 25, 2023

Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1]

Obesity

Obesity BMI Heart Failure Cardiovascular Disease

Cardiovascular Update

Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR?Preserved analysis

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Stay Connected